Autoimmune manifestations associated with myelodysplastic syndromes

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  J. Piette,et al.  Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. , 2017, Autoimmunity reviews.

[3]  A. Dueck,et al.  Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia , 2017, JAMA oncology.

[4]  O. Fain,et al.  Manifestations auto-immunes et inflammatoires des hémopathies lymphoïdes , 2017 .

[5]  M. Pirisi,et al.  Association between rheumatic diseases and cancer: results from a clinical practice cohort study , 2017, Internal and Emergency Medicine.

[6]  A. Mékinian,et al.  [Autoimmune and inflammatory disorders associated with lymphoid hematological malignancies]. , 2016, La Revue de medecine interne.

[7]  J. Piette,et al.  Relapsing Polychondritis Can Be Characterized by Three Different Clinical Phenotypes: Analysis of a Recent Series of 142 Patients , 2016, Arthritis & rheumatology.

[8]  M. Dougados,et al.  Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients , 2016, The Journal of Rheumatology.

[9]  O. Decaux,et al.  Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. , 2016, Leukemia research.

[10]  O. Decaux,et al.  Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML , 2018 .

[11]  E. Lee,et al.  Certain Autoimmune Manifestations Are Associated With Distinctive Karyotypes and Outcomes in Patients With Myelodysplastic Syndrome , 2016, Medicine.

[12]  A. Saraux,et al.  Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study , 2016, Annals of the rheumatic diseases.

[13]  J. Piette,et al.  Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. , 2016, Rheumatology.

[14]  E. Hellström-Lindberg,et al.  Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome , 2015, Oncotarget.

[15]  J. Salisbury,et al.  Chronic relapsing remitting Sweet syndrome – a harbinger of myelodysplastic syndrome , 2015, British journal of haematology.

[16]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[17]  U. Germing,et al.  Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes , 2015, Haematologica.

[18]  P. Fenaux,et al.  279 FREQUENCY OF AUTOANTIBODIES (AAB) IN MDS WITH AND WITHOUT CLINICAL AUTOIMMUNE DISORDERS (AID) , 2015 .

[19]  S. Scholl,et al.  Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review , 2014, European journal of haematology.

[20]  L. Rink,et al.  Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation. , 2014, Immunobiology.

[21]  P. Fenaux,et al.  Myelodysplastic syndromes , 2014, The Lancet.

[22]  Y. Erzin,et al.  Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature. , 2014, Rheumatology.

[23]  Pierre Fenaux,et al.  Inflammatory Arthritis in Patients With Myelodysplastic Syndromes , 2014, Medicine.

[24]  T. Chiba,et al.  Refractoriness of Intestinal Behçet's Disease with Myelodysplastic Syndrome Involving Trisomy 8 to Medical Therapies - Our Case Experience and Review of the Literature , 2013, Digestion.

[25]  S. Sait,et al.  Myelodysplastic syndromes and autoimmune diseases--case series and review of literature. , 2013, Leukemia research.

[26]  G. Mufti,et al.  The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome , 2013, Haematologica.

[27]  J. Maciejewski,et al.  Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome , 2012, The Journal of Immunology.

[28]  P. Vyas,et al.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.

[29]  O. Fain,et al.  Manifestations systémiques et auto-immunes des syndromes myélodysplasiques , 2011 .

[30]  P. Fenaux,et al.  [Systemic and autoimmune manifestations in myelodysplastic syndromes]. , 2011, La Revue de medecine interne.

[31]  D. Henrion,et al.  Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study , 2011, Arthritis care & research.

[32]  Sophie Park,et al.  The autoimmune manifestations associated with myelodysplastic syndrome respond to 5‐azacytidine: a report on three cases , 2011, British journal of haematology.

[33]  P. Wallace,et al.  Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. , 2011, Leukemia research.

[34]  L. Mouthon,et al.  The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort , 2011, Medicine.

[35]  Jinlan Pan,et al.  Pulmonary Alveolar Proteinosis as a Terminal Complication in a Case of Myelodysplastic Syndrome with idic(20q–) , 2009, Acta Haematologica.

[36]  T. Hügle,et al.  Allogeneic hematopoietic SCT for patients with autoimmune diseases , 2009, Bone Marrow Transplantation.

[37]  R. Pfeiffer,et al.  Risks of myeloid malignancies in patients with autoimmune conditions , 2009, British Journal of Cancer.

[38]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[39]  J. K. Ahn,et al.  Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. , 2008, Rheumatology.

[40]  E. Papadavid,et al.  Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[41]  Yulan Liu,et al.  Concurrent Inflammatory Bowel Disease and Myelodysplastic Syndrome: Report of Nine New Cases and a Review of the Literature , 2008, Digestive Diseases and Sciences.

[42]  J. Piette,et al.  Vasculitides associated with malignancies: analysis of sixty patients. , 2007, Arthritis and rheumatism.

[43]  G. Mufti,et al.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). , 2007, Blood.

[44]  J. Salisbury,et al.  Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5‐azacytidine , 2007, The British journal of dermatology.

[45]  A. Zanella,et al.  Anti-erythroblast autoimmunity in early myelodysplastic syndromes. , 2007, Haematologica.

[46]  D. Marisavljević,et al.  Immunologic abnormalities in myelodysplastic syndromes , 2006, Medical oncology.

[47]  A. Tzankov,et al.  Over‐expression of tumor necrosis factor‐alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis , 2005, European journal of haematology.

[48]  P. Vyas,et al.  Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. , 2005, Blood.

[49]  F. Bouali,et al.  Manifestations immunes associes aux syndromes mylodysplasiques. tude prospective de 40 patients , 2005 .

[50]  F. Bouali,et al.  [Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients)]. , 2005, La Revue de medecine interne.

[51]  S. Giannouli,et al.  Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. , 2004, Rheumatology.

[52]  H. Eom,et al.  Cyclosporine A in the Treatment of a Patient with Immune Thrombocytopenia Accompanied by Myelodysplastic Syndrome and Nephrotic Syndrome , 2003, Acta Haematologica.

[53]  G. Espinosa,et al.  Myelodysplastic and Myeloproliferative Syndromes Associated with Giant Cell Arteritis and Polymyalgia Rheumatica: A Coincidental Coexistence or a Causal Relationship? , 2002, Clinical Rheumatology.

[54]  C. Graf,et al.  Remitting Seronegative Symmetrical Synovitis with Pitting Oedema: A Study of 12 Cases , 2002, Clinical Rheumatology.

[55]  M. Saif,et al.  Autoimmune Phenomena in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia , 2002, Leukemia & lymphoma.

[56]  M. Hamidou,et al.  Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. , 2001, Seminars in arthritis and rheumatism.

[57]  S. Berthier,et al.  Mylodysplasies et maladies systmiques. Une association non fortuite , 2001 .

[58]  D. Chamone,et al.  Immunohematological Findings in Myelodysplastic Syndrome , 2001, Acta Haematologica.

[59]  J. Berthelot,et al.  Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. , 2000, Rheumatology.

[60]  G. Dolan,et al.  Relapsing polychondritis and myelodysplasia: a report of two cases and review of the current literature. , 2000, Clinical and laboratory haematology.

[61]  M. Okada,et al.  Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. , 1997, International journal of hematology.

[62]  W. Miller,et al.  Autoimmune phenomena in patients with myelodysplastic syndromes. , 1997, Leukemia & lymphoma.

[63]  B. Johansson,et al.  Immune‐mediated complications in patients with myelodysplastic syndromes – clinical and cytogenetic features , 1995, European journal of haematology.

[64]  J. Piette,et al.  Myelodysplasia and relapsing polychondritis. , 1995, The Journal of rheumatology.

[65]  F. van Rhee,et al.  Coombs negative haemolytic anaemia responding to intravenous immunoglobulins in a patient with myelodysplastic syndrome. , 2008, Clinical and laboratory haematology.

[66]  W. Su,et al.  Rheumatic manifestations in myelodysplastic syndromes. , 1991, The Journal of rheumatology.